SEC Form 5 · accession 0000899243-18-003902

Whitehawk Therapeutics, Inc. · WHWK

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Table I — non-derivative securities

Table II — derivative securities

Explanation of responses

• F1Consists of (i) 1,571,475 shares of Common Stock owned directly by Kearny Venture Partners, L.P., or KVP, and (ii) 32,051 shares of Common Stock owned directly by Kearny Venture Partners Entrepreneurs Fund, L.P., or KVPE. The general partner of both KVP and KVPE is Kearny Venture Associates, L.L.C., or KVA. KVA has the sole voting and investment control over the shares owned by KVP and KVPE. The Managing Members of KVA share in the voting and investment control over such shares controlled by KVA. The Managing Members of KVA are Caley Castelein, Richard Spalding and James Shapiro. None of the Managing Members of KVA has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. On December 22, 2017, Revelation TWHVP, LLC and TWHPV SPV, LLC, or the TWHVP entities,
• F2(Continued from footnote 1) were liquidated and their shares distributed on a pro rata basis to their members. Prior to this liquidation, Kearny Venture Associates II, LLC, or KVA II, was the Managing Member of the TWHVP entities. The Managing Members of KVA II were Caley Castelein, Andrew Jensen and Anupam Dalal. None of the Managing Members of KVA II had individual voting or investment power with respect to such shares and each disclaims past beneficial ownership of such shares except to the extent of any pecuniary interest therein.
• F3Consists of 10,920 shares of Common Stock distributed to Caley Castelein pursuant to the liquidation of the TWHVP entities.